<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<!DOCTYPE ichicsr SYSTEM "http://www.fda.gov/cder/aerssub/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
  <ichicsrmessageheader lang="en">
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>2.0</messageformatrelease>
    <messagenumb>CEL000000000001289221</messagenumb>
    <messagesenderidentifier>CELGENE</messagesenderidentifier>
    <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20130125102653</messagedate>
  </ichicsrmessageheader>
  <safetyreport lang="en">
    <safetyreportversion lang="en">0</safetyreportversion>
    <safetyreportid lang="en">CA-CELGENEUS-028-21880-13013465</safetyreportid>
    <primarysourcecountry>CA</primarysourcecountry>
    <occurcountry>CA</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20130125</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20130122</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20130122</receiptdate>
    <additionaldocument>2</additionaldocument>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb lang="en">CA-CELGENEUS-028-21880-13013465</companynumb>
    <medicallyconfirm>1</medicallyconfirm>
    <primarysource>
      <reportergivename>Ghislain</reportergivename>
      <reporterfamilyname>Cournoyer</reporterfamilyname>
      <reporterstreet>145 Avenue de la Providence</reporterstreet>
      <reportercity>Lachute</reportercity>
      <reporterstate>QC</reporterstate>
      <reportercountry>CA</reportercountry>
      <qualification>1</qualification>
    </primarysource>
    <sender>
      <sendertype>1</sendertype>
      <senderorganization>CELGENEUS</senderorganization>
      <senderdepartment>Global Drug Safety</senderdepartment>
      <sendertitle>Manager</sendertitle>
      <sendergivename>Vivian</sendergivename>
      <senderfamilyname>Fonseca</senderfamilyname>
      <senderstreetaddress>300 Connell Drive, Suite 6000</senderstreetaddress>
      <sendercity>Berkeley Heights</sendercity>
      <senderstate>NJ</senderstate>
      <senderpostcode>07922</senderpostcode>
      <sendercountrycode>US</sendercountrycode>
      <sendertel>9082190331</sendertel>
      <senderfax>9086739115</senderfax>
      <senderemailaddress>vfonseca@celgene.com</senderemailaddress>
    </sender>
    <receiver>
      <receivertype>2</receivertype>
      <receiverorganization>FDAPM</receiverorganization>
      <receivergivename>Roger</receivergivename>
      <receivermiddlename>A</receivermiddlename>
      <receiverfamilyname>Goetsch</receiverfamilyname>
      <receivercountrycode>US</receivercountrycode>
    </receiver>
    <patient lang="en">
      <patientinitial>M-B</patientinitial>
      <patientbirthdateformat>102</patientbirthdateformat>
      <patientbirthdate>19270819</patientbirthdate>
      <patientsex>2</patientsex>
      <patientmedicalhistorytext lang="en">None Provided</patientmedicalhistorytext>
      <patientdeath>
        <patientdeathcause>
          <patientdeathreportmeddraversion>15.1</patientdeathreportmeddraversion>
          <patientdeathreport>10063378</patientdeathreport>
        </patientdeathcause>
      </patientdeath>
      <reaction>
        <primarysourcereaction lang="en">DECEASED</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10011906</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10011906</reactionmeddrapt>
        <termhighlighted>3</termhighlighted>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>REVLIMID</medicinalproduct>
        <obtaindrugcountry>CA</obtaindrugcountry>
        <drugauthorizationnumb>21-880</drugauthorizationnumb>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugauthorizationholder>Celgene Corporation</drugauthorizationholder>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext lang="en">10 Milligram</drugdosagetext>
        <drugdosageform lang="en">Capsules</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10028228</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20121012</drugstartdate>
        <actiondrug>6</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>LENALIDOMIDE</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10011906</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not Provided</drugresult>
        </drugreactionrelatedness>
      </drug>
      <summary lang="en">
        <narrativeincludeclinical lang="en">DECEASED

(CANADA) Initial information was received on 22Jan2013 via a health care professional from the prescriber's office regarding an 85 year old female patient who received Revlimid. This patient received Revlimid 10mg PO from 12Oct2012 for the treatment of multiple myeloma. Lot number and expiration date were not provided. Relevant medical history and concomitant medications were not included. Per a fax from the prescriber's office, the patient was deceased. The date and cause of death were not specified. The reporter did not assess the causal relationship of the death to Revlimid. Additional information cannot be requested from the prescriber as consent was not granted.</narrativeincludeclinical>
        <sendercomment lang="en">The temporal relationship between therapy and DECEASED suggests that a causal relationship is possible, but underlying multiple myeloma could provide an alternative explanation. Additional information regarding the patient's disease status prior to death, relevant medical history, concurrent illnesses, concomitant medications, details about the death and therapy details are necessary to assist in providing a more complete causality assessment; however, consent was not granted to request additional information from the prescriber.</sendercomment>
      </summary>
    </patient>
  </safetyreport>
</ichicsr>
